Development and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL)

OBJECTIVES: Relapsing polychondritis (RP) is a rare, multisystem inflammatory disease characterized by heterogeneous clinical manifestations and a substantial impact on patients' daily functioning and well-being. Health-related quality of life (HR-QoL) in RP remains insufficiently characterized, and no disease-specific measurement tool is available so far. This study aimed to develop and validate the RP-QoL, a multilingual, patient-reported outcome instrument specifically designed to assess HR-QoL in individuals with RP. METHODS: The RP-QoL was developed within the European Reference Network ReCONNET using a structured four-step approach: (1) identification of relevant HR-QoL domains through systematic literature review, an international patient survey, and expert consensus; (2) item generation; (3) pilot testing including cognitive debriefing; and (4) comprehensive psychometric validation. Validation analyses included assessment of internal consistency, structural validity, construct validity, convergent validity with the SF-36, and criterion-related validity. RESULTS: Domain identification incorporated input from 274 patients across 22 countries, leading to a 31-item pilot questionnaire with a 28-day recall period and 5-point response scale. Cognitive debriefing confirmed clarity, relevance, and feasibility. Validation in 239 patients from 19 countries (median age 55 years; 80% female) demonstrated excellent internal consistency (Cronbach's α = 0.96). Exploratory factor analysis supported near-unidimensionality, with the first factor explaining 46.6% of variance. RP-QoL scores correlated strongly with disease impact (ρ = -0.62, p< 0.0001) and SF-36 physical (ρ = 0.65) and mental (ρ = 0.55, p< 0.0001) components (both p< 0.0001, p< 0.0001). Discriminative ability was high (AUC = 0.87). CONCLUSION: The RP-QoL is the first validated, disease-specific HR-QoL instrument for RP, with robust psychometric performance and applicability in both clinical practice and research.

Authors

Institutions

Publication Details

Journal
Lara D. Veeken
Published
2026-06-30
DOI
https://doi.org/10.1093/rheumatology/keag348
Primary Topic
Otitis Media and Relapsing Polychondritis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL)

Alexis Mathian, Paolo Semeraro, Cédric Sztejkowski, António Lamas et al.
Lara D. Veeken
Otitis Media and Relapsing Polychondritis
article

Development and validation of a Relapsing Polychondritis disease-specific Quality of Life instrument (ERN ReCONNET RP-QoL)

Alexis Mathian, Paolo Semeraro, Cédric Sztejkowski, António Lamas, Philippe Mertz, Christina Düsing, Francesca Crisafulli, Simona Rednic, Guillem Policarpo Torres, C F Vasconcelos, Thomas Rose, A. Armengou, Lou Kawka, H Devilliers, A POZZI, Camelia Bucșa, Jun Shimizu, Ana del Cielo Pérez Jaén, Piette Jc, Teodora Neagu, Mihaela Resteu, Sofia Silva-Ribeiro, Laura Damian, Raquel Faria, Cristina Pamfil, for the ERN ReCONNET, Aman Sharma, Oliver Sander, Marcella Ferrada, Lisa Matthews, Laurent Arnaud
article en

Abstract

OBJECTIVES: Relapsing polychondritis (RP) is a rare, multisystem inflammatory disease characterized by heterogeneous clinical manifestations and a substantial impact on patients' daily functioning and well-being. Health-related quality of life (HR-QoL) in RP remains insufficiently characterized, and no disease-specific measurement tool is available so far. This study aimed to develop and validate the RP-QoL, a multilingual, patient-reported outcome instrument specifically designed to assess HR-QoL in individuals with RP. METHODS: The RP-QoL was developed within the European Reference Network ReCONNET using a structured four-step approach: (1) identification of relevant HR-QoL domains through systematic literature review, an international patient survey, and expert consensus; (2) item generation; (3) pilot testing including cognitive debriefing; and (4) comprehensive psychometric validation. Validation analyses included assessment of internal consistency, structural validity, construct validity, convergent validity with the SF-36, and criterion-related validity. RESULTS: Domain identification incorporated input from 274 patients across 22 countries, leading to a 31-item pilot questionnaire with a 28-day recall period and 5-point response scale. Cognitive debriefing confirmed clarity, relevance, and feasibility. Validation in 239 patients from 19 countries (median age 55 years; 80% female) demonstrated excellent internal consistency (Cronbach's α = 0.96). Exploratory factor analysis supported near-unidimensionality, with the first factor explaining 46.6% of variance. RP-QoL scores correlated strongly with disease impact (ρ = -0.62, p< 0.0001) and SF-36 physical (ρ = 0.65) and mental (ρ = 0.55, p< 0.0001) components (both p< 0.0001, p< 0.0001). Discriminative ability was high (AUC = 0.87). CONCLUSION: The RP-QoL is the first validated, disease-specific HR-QoL instrument for RP, with robust psychometric performance and applicability in both clinical practice and research.

Lara D. Veeken
Inserm (FR), St. Marianna University School of Medicine (JP), Universidade do Porto (PT), Iuliu Hațieganu University of Medicine and Pharmacy (RO), Brescia University (US), Sorbonne Université (FR), Düsseldorf University Hospital (DE), Assistance Publique – Hôpitaux de Paris (FR), Laboratoire National de Référence (MA), Health Awareness (United States) (US), Hospital de Santo António (PT), Centre d'Immunologie et des Maladies Infectieuses (FR), Maison des Sciences sociales et des Humanités de Dijon (FR), Hôpitaux Universitaires de Strasbourg (FR), Hospital Universitari de Girona Doctor Josep Trueta (ES), Centre Hospitalier de Versailles (FR), Center for Rheumatology (US), Hôpital Tenon (FR), Heinrich Heine University Düsseldorf (DE), Post Graduate Institute of Medical Education and Research (IN), Charité - Universitätsmedizin Berlin (DE), University of Brescia (IT)
Openalex Percentile: Top 6%
Otitis Media and Relapsing Polychondritis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.